BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

504 related articles for article (PubMed ID: 32281301)

  • 21. Metabolic Tumor Volume Change Predicts Long-term Survival and Histological Response to Preoperative Chemotherapy in Locally Advanced Esophageal Cancer.
    Makino T; Yamasaki M; Tanaka K; Masuike Y; Tatsumi M; Motoori M; Kimura Y; Hatazawa J; Mori M; Doki Y
    Ann Surg; 2019 Dec; 270(6):1090-1095. PubMed ID: 29727327
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Prognostic value of preoperative [
    Ding J; Qiu J; Hao Z; Huang H; Liu Q; Liu W; Ren C; Hacker M; Zhang T; Wu W; Huo L; Li X
    Eur J Nucl Med Mol Imaging; 2023 May; 50(6):1780-1791. PubMed ID: 36695823
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Evaluation of response using FDG-PET/CT and diffusion weighted MRI after radiochemotherapy of pancreatic cancer: a non-randomized, monocentric phase II clinical trial-PaCa-DD-041 (Eudra-CT 2009-011968-11).
    Zimmermann C; Distler M; Jentsch C; Blum S; Folprecht G; Zöphel K; Polster H; Troost EGC; Abolmaali N; Weitz J; Baumann M; Saeger HD; Grützmann R
    Strahlenther Onkol; 2021 Jan; 197(1):19-26. PubMed ID: 32638040
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Prognostic value of
    Lee JR; Almuhaimid TM; Roh JL; Oh JS; Kim SJ; Kim JS; Choi SH; Nam SY; Kim SY
    J Surg Oncol; 2018 Sep; 118(4):644-650. PubMed ID: 30132891
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Prognostic impact of the
    Goksel S; Cengiz A; Ozturk H; Yurekli Y
    J Cancer Res Ther; 2021; 17(4):925-930. PubMed ID: 34528543
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Prognostic value of PERCIST and PET/CT metabolic parameters after neoadjuvant treatment in patients with esophageal cancer.
    Martínez A; Infante JR; Quirós J; Rayo JI; Serrano J; Jiménez P; Lavado MC; Baena Á
    Rev Esp Med Nucl Imagen Mol (Engl Ed); 2022; 41(6):360-367. PubMed ID: 36243656
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Metabolic tumour and nodal response to neoadjuvant chemotherapy on FDG PET-CT as a predictor of pathological response and survival in patients with oesophageal adenocarcinoma.
    Moore JL; Subesinghe M; Santaolalla A; Green M; Deere H; Van Hemelrijck M; Lagergren J; Chicklore S; Maisey N; Gossage JA; Kelly M; Baker CR; Davies AR;
    Eur Radiol; 2023 May; 33(5):3647-3659. PubMed ID: 36920518
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Metabolic activity by FDG-PET/CT after neoadjuvant chemotherapy in borderline resectable and locally advanced pancreatic cancer and association with survival.
    Lee W; Oh M; Kim JS; Park Y; Kwon JW; Jun E; Song KB; Lee JH; Hwang DW; Yoo C; Kim KP; Jeong JH; Chang HM; Ryoo BY; Park SY; Kim SC
    Br J Surg; 2021 Dec; 109(1):61-70. PubMed ID: 34378010
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Baseline Characteristics and Use of Pretherapeutic 18 F-Fluorodeoxyglucose-PET for Pancreatic Cancer.
    Carlson DM; Abdelrahman AM; Adjei Antwi SK; Tomlinson JL; Trivedi K; Karbhari A; Patnam Gopal Chetty N; Halfdanarson TR; Goenka AH; Truty MJ
    J Am Coll Surg; 2024 Jul; 239(1):9-17. PubMed ID: 38445645
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Heterogeneity index evaluated by slope of linear regression on
    Kim YI; Kim YJ; Paeng JC; Cheon GJ; Lee DS; Chung JK; Kang KW
    Eur J Nucl Med Mol Imaging; 2017 Nov; 44(12):1995-2003. PubMed ID: 28634684
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Prognostic significance of interim
    Lee SY; Seo HJ; Kim S; Eo JS; Oh SC
    Asia Pac J Clin Oncol; 2018 Oct; 14(5):e302-e309. PubMed ID: 29226597
    [TBL] [Abstract][Full Text] [Related]  

  • 32. An evaluation of the response to neoadjuvant chemotherapy for osteosarcoma of extremities: PERCIST versus RECIST 1.1 criteria after long-term follow-up.
    Xu J; Li Y; Xie L; Sun X; Cai Z; Wang S; Wang Q; Sun K; Guo W
    Ann Nucl Med; 2022 Jun; 36(6):553-561. PubMed ID: 35380350
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The early prediction of pathological response to neoadjuvant chemotherapy and prognosis: comparison of PET Response Criteria in Solid Tumors and European Organization for Research and Treatment of Cancer criteria in breast cancer.
    Lian W; Liu C; Gu B; Zhang J; Lu L; Pan H; Yao Z; Wang M; Song S; Zhang Y; Yang Z
    Nucl Med Commun; 2020 Mar; 41(3):280-287. PubMed ID: 32032193
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Comparing prognostic factors of Glut-1 expression and maximum standardized uptake value by FDG-PET in patients with resectable pancreatic cancer.
    Takahashi M; Nojima H; Kuboki S; Horikoshi T; Yokota T; Yoshitomi H; Furukawa K; Takayashiki T; Takano S; Ohtsuka M
    Pancreatology; 2020 Sep; 20(6):1205-1212. PubMed ID: 32819845
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Response to neoadjuvant chemotherapy for breast cancer judged by PERCIST - multicenter study in Japan.
    Kitajima K; Nakatani K; Yamaguchi K; Nakajo M; Tani A; Ishibashi M; Hosoya K; Morita T; Kinoshita T; Kaida H; Miyoshi Y
    Eur J Nucl Med Mol Imaging; 2018 Sep; 45(10):1661-1671. PubMed ID: 29754160
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Prognostic values of mid-radiotherapy
    Kim N; Cho H; Yun M; Park KR; Lee CG
    Radiat Oncol; 2019 Feb; 14(1):27. PubMed ID: 30717809
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Efficacy evaluation of neoadjuvant immunotherapy plus chemotherapy for non-small-cell lung cancer: comparison of PET/CT with postoperative pathology.
    Cheng Y; Chen ZY; Huang JJ; Shao D
    Eur Radiol; 2023 Oct; 33(10):6625-6635. PubMed ID: 37515634
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Prediction of tumour grade and survival outcome using pre-treatment PET- and MRI-derived imaging features in patients with resectable pancreatic ductal adenocarcinoma.
    Dunet V; Halkic N; Sempoux C; Demartines N; Montemurro M; Prior JO; Schmidt S
    Eur Radiol; 2021 Feb; 31(2):992-1001. PubMed ID: 32851447
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Prognostic value of metabolic tumor volume and total lesion glycolysis from ¹⁸F-FDG PET/CT in lymph node metastases and risk stratification of endometrial carcinoma.
    Liu DD; Li J; Li X; Xie L; Qin L; Peng F; Cheng MH
    J Gynecol Oncol; 2019 Nov; 30(6):e89. PubMed ID: 31576685
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Comparison of RECIST, EORTC criteria and PERCIST for evaluation of early response to chemotherapy in patients with non-small-cell lung cancer.
    Shang J; Ling X; Zhang L; Tang Y; Xiao Z; Cheng Y; Guo B; Gong J; Huang L; Xu H
    Eur J Nucl Med Mol Imaging; 2016 Oct; 43(11):1945-53. PubMed ID: 27236466
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 26.